个人简历

查晓明，男，1980年5月生，副研究员，博士生导师。2002年获中国药科大学化学制药学士学位，2007年获中国药科大学药物化学博士学位。同年留校进入新药筛选中心工作任助理研究员，2011年6月任副研究员，2014年12月任工学院副研究员。2013年至2014年，作为访问学者在哈佛大学化学和化学生物学系诺贝尔化学奖得主E. J. Corey教授课题组从事有机合成研究工作。入选江苏省“六大人才高峰”（2016），江苏省“双创计划”科技副总（2018）等项目。

研究领域

抗肿瘤创新药物研究：表观遗传调控相关的组蛋白去甲基化酶LSD1抑制剂、肿瘤代谢异常相关的异柠檬酸脱氢酶IDH1/2突变抑制剂等
药物合成新方法、新工艺研究
化学成像功能探针的制备及生物学研究

近期论文

[1] S. Y. Xu#, C. Zhou#, R. F. Liu, Q. H. Zhu, Y. G. Xu*, F. Lan*, X. M. Zha*, Optimization of 5-Arylidene Barbiturates as Potent, Selective, Reversible LSD1 Inhibitors for the Treatment of Acute Promyelocytic Leukemia. Bioorganic & Medicinal Chemistry, 2018, 26(15): 4871-4880.
[2] Y. S. Ren #, L. L. Zhang #, Z. Y. Zhou #, Y. J. Luo, S. L. Wang *, S. T. Yuan, Y. Q. Gu, Y. G. Xu, X. M. Zha *, A New Lysosome-targetable Fluorescent Probe with a Large Stokes Shift for Detection of Endogenous Hydrogen Polysulfides in Living Cells,Analytica Chimica Acta, 2019, 1056, 117-124.
[3] T. F. Ma#, F. X. Zou#, S. Pusch#, Y. G. Xu, A. von Deimling, X. M. Zha*, Inhibitors of Mutant Isocitrate Dehydrogenase 1 and 2: an Update and Perspective,Journal of Medicinal Chemistry, 2018, 61(20): 8981-9003.
[4] Z. Y. Zhou#, T. F. Ma#, Q. H. Zhu, Y. G. Xu, X. M. Zha*, Recent Advances in Inhibitors of SIRT (sirtuin) 1/2: an Update and Perspective, Future Medicinal Chemistry, 2018, 10(8): 907-934.
[5] J. Y. Xi #, S. Y. Xu #, L. L. Zhang #, X. Y. Bi, Y. S. Ren,Y. C. Liu,Y. Q. Gu, Y. G. Xu, F. Lan, * X. M. Zha, * Design, Synthesis and Biological Activity of 4-(4-Benzyloxy)phenoxypiperidines as Selective and ReversibleLSD1 Inhibitors, Bioorganic Chemistry, 2018, 78, 7-16.
[6] F. X. Zou#, S. Pusch#, J. Hua#, T. F. Ma, L. J. Yang, Q. H. Zhu, Y. G. Xu, Y. Q. Gu, A. von Deimling*, X. M. Zha*,Identification of Novel Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 by Cross Docking-based Virtual Screening, Bioorganic & Medicinal Chemistry Letters, 2018, 28(3): 388-393.
[7] J. Y. Xi#, S. Y. Xu#, L. M. Wu#, T. F. Ma, R. F. Liu, Y. C. Liu, D. W. Deng, Y. Q. Gu, J. P. Zhou, F. Lan*, X. M. Zha*. Design, Ssynthesis and Biological Activity of 3-Oxoaminobenzenesulfonamides as Selective and Reversible LSD1 Inhibitors. Bioorganic Chemistry, 2017, 72, 182–189.
[8] T. F. Ma #, F. X. Zou#, S. Pusch, L. J. Yang, Q. H. Zhu, Y. G. Xu, Y. Q. Gu, A. von Deimling*, X. M. Zha*, Design, Synthesis and Biological Activity of 3-Pyrazine-2-yl-oxazolidin-2-ones as Novel, Potent and Selective Inhibitors of Mutant Isocitrate Dehydrogenase 1, Bioorganic & Medicinal Chemistry, 2017, 25(24): 6379-6387.
[9] X. M. Zha#, *, D. Lamba#,L. L. Zhang, Y. H. Lou, C. X. Xu, D. Kang, L. Chen, Y. G. Xu, L. Y. Zhang, A. De Simone, S. Samez, A. Pesaresi, J. Stojan, M. G. Lopez, J. Egea, V. Andrisano, M. Bartolini *, Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Agents for the Treatment of Alzheimer's Disease: Design, Synthesis Biological Evaluation and X-ray Crystallography, Journal of Medicinal Chemistry, 2016, 59(1): 114-131.
[10]C. Zhou, D. Kang, Y. G. Xu*, L. Y. Zhang, X. M. Zha*.Identification of Novel Selective Lysine Specific Demethylerase 1 (LSD1) Inhibitors Using a PharmacophoreBased Virtual Screening Combined with Multiple Docking. Chem. Biol. & Drug Design, 2015, 85(6): 659-671.封面文章